Orion Biotechnology is a clinical stage biotechnology company discovering and developing next-generation G Protein-Coupled Receptor (GPCR)-targeted therapeutics for the treatment of cancer and other serious diseases. We precision-engineer natural peptide and protein analogs to develop a novel class of highly potent drugs which unlock a set of high-value GPCR targets that have proved difficult to target using traditional drug classes. Orion’s breakthrough science and novel approach is led by a proprietary drug discovery platform that unlocks the discovery of analogs through efficient exploration of the GPCR-drug interface, allowing for the precision engineering of peptide and protein ligands to produce highly potent novel drug candidates with user-defined signaling profiles. The company is growing a multi-asset high-value portfolio of drug candidates with significant clinical potential, led by Orion’s first best-in-class analog, OB-002.
Privately Funded Company
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):